Promising results from HPTN 035, a phase II trial of two microbicides, were reported at the 2009 Retrovirus Conference.
Several anti-HIV microbicide trials have been conducted in recent years, but none have yielded positive results . . . until now. At this year’s Retrovirus Conference, Salim Abdool Karim presented the much-awaited results of HPTN 035, a phase II/IIb trial designed to assess the safety and efficacy of two microbicides for the prevention of HIV infection in women [Abstract 48LB].
More than 3000 women from Malawi, South Africa, Zambia, Zimbabwe, and the U.S. were randomized to receive 0.5% PRO 2000 gel, BufferGel, placebo gel, or no gel. (PRO 2000 gel is a polyanionic polymer intended to bind to positive charges on the surface of HIV and prevent it from entering cells. BufferGel increases the natural acidity of the vagina.) The three gel arms we…
Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)